The official advocacy organization for pharmacist women in the United States
Pharmacist Moms Group™
45,000+ Members
Over 6 Million posts, comments and reactions in 2020
60,000+ Followers on social media platforms
The Largest Community of Women Pharmacists in the US
Founded in 2017, Pharmacists Moms Group was created to provide women pharmacists the opportunity to network, collaborate and offer genuine feedback in a closed-door, trusted setting. The organization has quickly grown to over 45,000 members and 60,000 followers on our social media platforms.
While we may not be able to control what happens to us, we can ALWAYS control how we respond. Working on self-awareness and self-improvement will certainly create positive habits to help you when you are stuck.
Read on to learn more about Jennifer’s path to pharmacy ownership, and to learn how COVID-19 and the Oregon wildfires have impacted her business.
Miss America 2020, Camille Schrier, has been a proud, self-described “science nerd” for as long as she can remember. We caught up with Camille to get a student’s perspective on the future of the profession.
Dalpiciclib combined with endocrine therapy significantly enhances progression-free survival in HR+/HER2– breast cancer, as shown in the DAWNA-A trial.
These health care professionals are crucial to optimizing safety in medication therapy, addressing policy barriers, and the collaboration with others in the field.
Panelists discuss how pharmacists play a crucial role in biliary tract cancer management by leveraging their detailed medication knowledge to assist with treatment selection, develop comprehensive monitoring plans (especially for hyperphosphatemia with FGFR inhibitors and cardiac monitoring with HER2 therapies), educate patients about unique toxicities and self-management strategies, create clinic workflow algorithms for toxicity management, and advocate for maximizing time on therapy as long as patients maintain response or stable disease given the limited treatment options available for this rare cancer type.
Panelists discuss how trastuzumab deruxtecan demonstrated a 22% overall response rate in patients with biliary tract cancer (56.3% in HER2 3+ patients) with 7.4 months progression-free survival in the tumor-agnostic DESTINY-PanTumor02 trial, while zanidatamab showed a 52% confirmed response rate with 7.2 months progression-free survival in HER2 3+ patients in the biliary-specific HERIZON-BTC-01 trial, with treatment selection between these agents requiring individualized case-by-case decisions based on toxicity profiles, dosing schedules, and patient-specific factors since no head-to-head comparison data exist.
Panelists discuss how HER2-targeted agents in biliary tract cancers include trastuzumab deruxtecan (an antibody-drug conjugate that acts like a “smart missile” delivering cytotoxic payload to HER2-expressing cells with risks of pneumonitis and myelosuppression) and zanidatamab (a bispecific antibody targeting 2 different HER2 epitopes simultaneously for enhanced cytotoxicity with primarily antibody-related toxicities like cardiac effects and diarrhea but without chemotherapy-related adverse effects).
Official Media Partner
.png)
Official CE Partner
Founder of Women Pharmacist Day
